Abstract
The Cyclin-Dependent Kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents. The CDK inhibitors can effectively suppress the excessive proliferation of tumor cells by inducing cell cycle arrest. In recent years, a large number of CDK inhibitors have entered pre-clinical and/or clinical trials. Among these compounds, the selective CDK4/6 inhibitor Palbociclib has been approved by FDA for breast cancer treatment. Moreover, Palbociclib demonstrated promising antitumor potential as monotherapy or combined therapy in numerous clinical trials. Herein, we provide a brief review focused on the recent progress of clinical studies about Palbociclib.
Keywords: Cyclin-Dependent Kinases (CDKs), palbociclib, monotherapy, combined therapy, anti-cancer, cell cycle arrest.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
Volume: 18 Issue: 9
Author(s): Fengquan Chen, Chunxi Liu, Jian Zhang, Wenfang Xu*Yingjie Zhang*
Affiliation:
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong,China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong,China
Keywords: Cyclin-Dependent Kinases (CDKs), palbociclib, monotherapy, combined therapy, anti-cancer, cell cycle arrest.
Abstract: The Cyclin-Dependent Kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents. The CDK inhibitors can effectively suppress the excessive proliferation of tumor cells by inducing cell cycle arrest. In recent years, a large number of CDK inhibitors have entered pre-clinical and/or clinical trials. Among these compounds, the selective CDK4/6 inhibitor Palbociclib has been approved by FDA for breast cancer treatment. Moreover, Palbociclib demonstrated promising antitumor potential as monotherapy or combined therapy in numerous clinical trials. Herein, we provide a brief review focused on the recent progress of clinical studies about Palbociclib.
Export Options
About this article
Cite this article as:
Chen Fengquan , Liu Chunxi , Zhang Jian , Xu Wenfang *, Zhang Yingjie*, Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (9) . https://dx.doi.org/10.2174/1871521409666170412123500
DOI https://dx.doi.org/10.2174/1871521409666170412123500 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imidazoquinolines: Recent Developments in Anticancer Activity
Mini-Reviews in Medicinal Chemistry Immunotherapy and Cancer Vaccines in the Management of Breast Cancer
Current Pharmaceutical Design The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer
Current Cancer Drug Targets Respiration and Energy Homeostasis
Current Respiratory Medicine Reviews Aptamers: Potential Applications to Pancreatic Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Hyperthermia-Mediated Docetaxel Derivative Release from Temperature-Sensitive Nanomedicines
Drug Delivery Letters Targeting Mitogen-Activated Protein Kinase Phosphatase-1 (MKP-1): Structure-Based Design of MKP-1 Inhibitors and Upregulators
Current Medicinal Chemistry Immune Receptors, Cadherins and their Interactions
Current Immunology Reviews (Discontinued) The Role of microRNA-126 in Vascular Homeostasis
Current Vascular Pharmacology FbD Supported Development and In Vitro Evaluation of Carbomer based Resveratrol Loaded Topical Antipsoriatic Nanoemulgel for its Targeted Skin Delivery
Pharmaceutical Nanotechnology Breast Cancer Risks in Premenopausal Women: A Review
Current Women`s Health Reviews Toxicophoric and Metabolic In Silico Evaluation of Benzimidazole and Phenylbenzamide Derivatives with Potential Application as Anticancer Agents
Drug Metabolism Letters Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Cancer Therapy-Induced Residual Bone Marrow Injury: Mechanisms of Induction and Implication for Therapy
Current Cancer Therapy Reviews OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Editorial (Thematic Issue: Structure-Function Based Drug Design for Cancer Therapeutics)
Current Pharmaceutical Biotechnology Double Edge Sword Behavior of Carbendazim: A Potent Fungicide With Anticancer Therapeutic Properties
Anti-Cancer Agents in Medicinal Chemistry The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Modulation of Angiogenesis by Inflammatory Markers and the Role of Matrix Metalloproteinases in an Endothelial Cell/Fibroblast Co-culture System
Current Angiogenesis (Discontinued)